Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Shares Outstanding (Weighted Average) (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $27.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 1.89% year-over-year to $27.9 million, compared with a TTM value of $27.9 million through Sep 2025, up 1.89%, and an annual FY2024 reading of $27.3 million, up 2.71% over the prior year.
  • Shares Outstanding (Weighted Average) was $27.9 million for Q3 2025 at Fennec Pharmaceuticals, up from $27.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $27.9 million in Q3 2025 and bottomed at $26.0 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $26.7 million, with a median of $26.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) soared 30.69% in 2021, then grew 0.06% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $26.0 million in 2021, then rose by 1.04% to $26.3 million in 2022, then grew by 1.14% to $26.6 million in 2023, then rose by 2.71% to $27.3 million in 2024, then grew by 2.18% to $27.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for FENC at $27.9 million in Q3 2025, $27.6 million in Q2 2025, and $27.6 million in Q1 2025.